Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Kudos, george, as your prediction on interest rates are surely propelling stocks forward ... for today, at least.
I'm glad I read the other replies to you ... it calmed me down as you have no idea why he is not posting anymore.
I know it's been close to three years and I hope the reason is not similar to the one that caused stoppage by bennyboy and ipman, may they rest in peace.
Instead, I hope it is a conflict of interest reason.
Hosai, don't you mean .025?
12x, what board meeting ... or are you jesting?
Better than the 7:30 slots he usually gets.
What should be added to this headline are the words: "but, did not slow cognitive decline."
https://alzheimersnewstoday.com/news/amx0035-improves-core-alzheimers-related-biomarkers-study/
Try ...
... for the published date.
george, thank you, but did you find any conferences earlier than this one in November?
On Monday, I took a stab at finding conferences, but found nothing. I know TGD likes "silence is golden," but three months with nothing. Sure would appreciate some great news before then, which is around the time of Q4 and FYE 2024 PR.
It is interesting that Dr. K doesn't claim to be associated with Anavex though 2-73 and 3-71 are noted in the article.
badger, not sure if the rest reads like this paragraph ...
... but, if it does, it is a waste of time to read any more. Anavex is not focusing/targeting on Aß. Any beneficial change in Aß due to blarcamesine is purely coincidental and is based on its overall performance to reduce Aß damage.
I don't think this writer understands that Aß clearance does not slow cognitive decline, much less stop it.
Steady and blue finch, does the YTD% have a starting point of the last trade of the prior year ($9.31) or the first trade of the new year ($5.90)?
Prayers for you, X, as you face those problems ... also, prayers from Bio wherever he is!
Someone certainly does not want this stock to go and stay above $28.
Hoskuld, I listened to the quarterly cc and the Canaccord Genuity presentation and I came away with the impression that Verona management is on top of all matters: marketing, sales, and distribution. If there were a problem, it might be the pharmacies listing Ohtuvayre in their systems, given it is a new product and it needs to establish an ordering pattern for it.
Hoping the patient numbers are higher within a year.
Have you seen or heard any info on EMA and/or UK filings/approval?
Given the boorish and boringness of this board this week, what is going on with SAVA as it is up $7 this week? Any thoughts?
P.S. Its MB is even worse than AVXL's as no posts there since Monday.
Not actually a "Hit" piece, but leaves negative impressions, anyway. Released earlier in late July ... must not have had the intended effect, so it tries again.
https://www.benzinga.com/news/24/08/40365322/top-3-health-care-stocks-that-may-crash-in-august
Possibly, it is being sold. Common when the founder takes "an exit, stage left!"
What a pile ... If one bought 1,000 shares of SAVA and AVXL at the each stock's peak in 2021, one would today have a $115,000 loss on SAVA and $25,000 on Anavex ... and for SAVA, the loss would have been $135,000 2 weeks ago. SAVA SP is manipulated by WS, which will take it up or down as WS wants ... even sold to the highest bidder.
T, another matter that has been ignored is that the dosed data is watered-down by those on 2-73 plus one/both of the other two drugs.
Those folks are on a version of 2-73 Plus depending upon the various dose levels of each. We know 2-73 Plus had some impact, but not much compared to SOC/placebo ... otherwise, there would be no 2-73 only group in the study.
IMO.
Thanks, bb, and I agree with your PM from yesterday.
P.S. It appears there were 40 participants in the placebo group who were not taking any DPZ or Memantine.
I am looking forward to the results of that group independent of the whole placebo group compared to those taking the other drugs ... in the trial and the OLE, too, just like the 56 blarcamesine-only participants.
Yes, Investor, the chart was found by williamssc in a July 29 article posted from bas.
Thank you, williamssc, that is what I was looking for and it includes a timeline measurement.
I appreciate your help ... and, of course, bas'.
Thanks, Investor, but I did not find that bar chart in this April presentation. I think it is a more recent one and may have been crafted by a poster here or on ST as it show three bars going vertical with Blarcamesine being the highest.
Hosai, IMO, those participants indicating a possible reversal where those on blarcamesine only (n = 56, total of 30mg and 50mg) and not taking any other drug. This finding might be disclosed in the peer review paper.
I am anxiously awaiting the data on the blarcamesine-only participants. 🤞
Does anyone have the link that shows the reduction in cognitive decline comparison between blarcamesine and the 'mabs. I believe it showed blarcamesine @ 48 weeks and the 'mabs at a longer period.
I believe this illustrates visually the impact of blarcamesine ... quicker, better and easier to administer.
Thank you in advance.
Is SAVA skyrocketing on a buyout? Not a stretch when top dog goes down … and company has no one qualified to replace him/her.
The one thing not addressed by frrol and others is that 81% of the dosed participants were also taking another drug(s), Cholinesterase inhibitors (ChEIs) or/and Memantine, per page 12 of the presentation of Dr. Sabbagh. Only 56 were taking blarcamesine only. It is possible that the TEAE’s were principally caused by the drugs’ interaction. It is all speculation as to blarcamesine's role in the dropouts.
Unfortunately, we haven’t seen any data on these 56 separately to know how well they did, using only blarcamesine. I’m sure Anavex has that data and will be using it in a proper manner. I am sure it will be shared with the EMA and with the fda, eventually.
From Alzheimer's Association ... Senate does something.
https://www.alz.org/news/2024/senate-passes-napa-reauthorization-act?WT.mc_id=enews2024_07_31&utm_source=enews-aff-67&utm_medium=email&utm_campaign=enews-2024-07-31&utm_content=homeoffice&utm_term=Story1
Thank you, Piotr Pietrzkiewicz, and to bas, too. Very telling! Good performance, blarcamesine and Anavex crew! 📣
Hosai, might the P2b/3 OLE serve as evidence of blarcamesine's prowess with 1) the placebo group reversing trends and 2) the dosed folks continuing to improve/decline less rapidly? If that were happening, especially #1, then it should be adequate for full approval ... as blarcamesine is causing ALL of this! IMO
Gosh, I thought the 4th quarter was in the second half.
How could I be so wrong?
Thank you, Hoskuld and Leo.
Found this as news on Fidelity ... not sure if significant or not?
Has there been any report on Dr. Jin's presentation?
meds, I think the shelf gets old/expired (2019) and SEC likes companies to update with other needed provisions by the companies.
First, how do you know that?
Second, he doesn't need to speak with any BP's because the BP members of the Consortium will be the partners, IMO. That is why they joined the Consortium.
Plus, bb, its volume is over 3.8 million. Its short position I think is 36%+. Maybe, the shorts are confused as to which company reported a 39% reduction in decline. ;)
sage and bb, is SAVA presenting @ AAIC? Might be up due to that if it were. Otherwise, probably a share offering in the works and WS needs a higher price.